Two months ago, analysts regarded a 20% reduction in cardiovascular events among obesity patients as the best-case scenario for Novo Nordisk A/S’s Wegovy (semaglutide injection 2.4mg). Today the vast SELECT trial hit that bullseye, driving Novo’s shares up by 18% to DKK1,285.60 ($188.67) as investors anticipate wider reimbursement and a further leap in demand.
SELECT: Novo Nordisk Comes Roaring Back
After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.
More from Cardiovascular
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.